Company Team Projects Media Contact


Lascco Announces granted US patent protecting its biomarker PSP for the diagnosis of sepsis

June 28, 2013

GENEVA, SWITZERLAND -- Lascco SA announced today announced today that the United States Patent and Trademark Office (USPTO) issued the US Patent No. 8,435,755, related to the use of its biomarker, Pancreatic Stone Protein (PSP), for the prediction of sepsis.

Earlier this year, similar patents for PSP were granted in Japan and in China. The PSP biomarker is currently under development in partnership with global diagnostic companies for use on immunochemistry analyzers.

About sepsis

Sepsis, a syndrome characterized by an overwhelming systemic response to infection, is among the leading causes of death in intensive care units and accounts for 40% of their total expenditure. Every year, 18 million individuals die from sepsis. In the United States alone, the estimate of cases amounts to 1 million per year. Despite tremendous research and increasing therapeutic efforts, mortality rates from sepsis remain disappointingly high, ranging between 30% and 50%, mostly attributed to misdiagnosis or delayed diagnosis.

About Lascco SA

LASCCO SA is a Swiss-based biotechnology company dedicated to the maturation of early-stage biomedical technologies. For more information, visit


Lascco S.A.

Rue de la Rôtisserie 8 - 1211 Geneva 3 – Switzerland

Phone: +41 (0)22 317 8881